Combination of HCV protease inhibitors with a surfactant

Details for Australian Patent Application No. 2006252553 (hide)

International Classifications

Event Publications

20 December 2007 PCT application entered the National Phase

PCT publication WO2006/130628 Priority application(s): WO2006/130628

29 March 2012 Application Accepted

Published as AU-B-2006252553

26 July 2012 Standard Patent Sealed

11 October 2012 Application for Amendment

The nature of the amendment is: Amend the Patentee to read Merck Sharp & Dohme Corp. . Address for service in Australia - Griffith Hack Level 29, Northpoint 100 Miller Street North Sydney NSW 2060 2006294633 7-[2-[4- (6-fluoro-3-methyl -1,2-benzisoxazol-5-yl) -1piperazinyl]ethyl] -2- ( 1-propynyl) -7h-pyrazolo- [ 4,3-e]-[1,2,4] -triazolo- [1,5-c] -pyrimidin5 amine Schering Corporation The nature of the amendment is: Amend the Patentee to read Merck Sharp & Dohme Corp. . Address for service in Australia - Gr

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.